The Weight Loss Atlas: Novo Nordisk trackerhttps://theweightlossatlas.com/companies/novo-nordisk/Novo Nordisk weight-loss and diabetes news from the Weight Loss Atlas: approvals, filings, company reports and what is coming next. Company statements are labeled as such.en-usFri, 30 Oct 2026 14:00:00 GMT Novo Nordisk second-quarter report: 2026 outlook raised and pipeline calendar givenhttps://theweightlossatlas.com/companies/novo-nordisk/#call-logatlas-novo-q2-2026-reportTue, 04 Aug 2026 12:00:00 GMTCompany reportCompany-reported: Novo Nordisk raised its 2026 outlook and listed a U.S. decision on CagriSema for the fourth quarter of 2026. The Atlas tracker summarizes what the report said about Wegovy, Ozempic, CagriSema and zenagamtide. FDA approves Wegovy HD, a 7.2 mg semaglutide dosehttps://theweightlossatlas.com/news/wegovy-hd/atlas-news-wegovy-hdThu, 19 Mar 2026 12:00:00 GMTApprovalA higher-dose version of the weekly Wegovy injection was approved by the FDA. Novo Nordisk files CagriSema with the FDAhttps://theweightlossatlas.com/news/cagrisema-filed/atlas-news-cagrisema-filedThu, 18 Dec 2025 12:00:00 GMTFilingNovo Nordisk submitted CagriSema, a weekly amylin-plus-GLP-1 combination, for U.S. review.